C V Starr & Co. Inc. Buys New Stake in Celularity, Inc. $CELU

C V Starr & Co. Inc. purchased a new position in Celularity, Inc. (NASDAQ:CELU) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity accounts for 0.8% of C V Starr & Co. Inc.’s portfolio, making the stock its 4th biggest holding. C V Starr & Co. Inc. owned about 2.64% of Celularity at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CELU. Acadian Asset Management LLC bought a new position in Celularity during the 1st quarter valued at $34,000. XTX Topco Ltd boosted its stake in Celularity by 106.4% in the second quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock valued at $42,000 after acquiring an additional 11,057 shares during the period. Bank of America Corp DE boosted its position in Celularity by 1,538.1% during the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after purchasing an additional 35,023 shares during the period. Jane Street Group LLC bought a new position in shares of Celularity during the fourth quarter worth about $46,000. Finally, Geode Capital Management LLC grew its position in Celularity by 15.0% in the 4th quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock worth $178,000 after purchasing an additional 20,876 shares during the last quarter. 19.02% of the stock is owned by hedge funds and other institutional investors.

Celularity Stock Up 4.3%

NASDAQ:CELU opened at $0.80 on Friday. The stock has a fifty day simple moving average of $0.72 and a 200 day simple moving average of $0.99. The firm has a market capitalization of $23.16 million, a price-to-earnings ratio of -0.24 and a beta of 0.54. Celularity, Inc. has a 1-year low of $0.56 and a 1-year high of $4.01.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Celularity from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $6.00.

Celularity Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.